|
|
||||||||
University of California, San Diego, School of Medicine, La Jolla, California and Veterans Administration Hospital, La Jolla, California
Correspondence: For reprints contact: Samuel E. Halpern, Div. of Nuclear Medicine, University Hospital of San Diego County, 225 West Dickinson St., San Diego, Calif. 92103.
ABSTRACT
Studies were performed that indicate that normal, healthy individuals have a lower thyroidal uptake of 131I following a capsule dose of 131I than they do following a liquid dose. Two possible mechanisms for this are offered, the first being the variable amount of time it takes for the ingested capsule to dissolve completely and the second being the formation of iodine gelatin complexes in the GI tract. In the latter case, the labeled iodine would not appear to be in a form that would allow it to be trapped by the thyroid gland. It is recommended that if early uptake values are important in assessing the clinical state of the patient, liquid 131I be used in preference to capsulized 131I. Furthermore, the possibility exists that the fall in 131I uptake values noted in the past several years may in part be due to the widespread use of 131I capsules.
This article has been cited by other articles:
![]() |
M.-D. Yu, W.-S. Huang, C.-C. Cherng, and S. M. Shaw The Effect of Formulation on Reduced Radioiodide Thyroid Uptake J. Nucl. Med., January 1, 2002; 43(1): 56 - 60. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |